Effects of switching from imiglucerase to velaglucerase alfa without dose reduction nor wash out in type 1 Gaucher disease

Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):94-6. doi: 10.1016/j.bcmd.2013.12.004. Epub 2014 Jan 7.
No abstract available

Publication types

  • Letter

MeSH terms

  • Drug Substitution
  • Enzyme Replacement Therapy*
  • Gaucher Disease / drug therapy*
  • Glucosylceramidase / therapeutic use*
  • Humans
  • Time Factors
  • Treatment Outcome

Substances

  • Glucosylceramidase
  • Velaglucerase alfa, human
  • imiglucerase